Home / Congress Presentations / C3G and Primary IC-MPGN / American Society of Nephrology (ASN) Kidney Week 2025
Landing
American Society of Nephrology (ASN) Kidney Week 2025
Pegcetacoplan for 52 weeks results in sustained proteinuria reduction to remission (≤0.5 g/g) and normalization (≤0.2 g/g): Phase 3 VALIANT trial
Pegcetacoplan for adolescents and adults with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis: enrollment status of the VALE extension
Pegcetacoplan for 52 weeks maintains proteinuria reduction and eGFR stabilization for pediatric patients: Phase 3 VALIANT subgroup analysis
Pegcetacoplan for 52 weeks maintained proteinuria reduction regardless of immunosuppressant use or nephrotic range proteinuria at baseline: VALIANT subgroup analysis
Human factors validation of a pegcetacoplan on-body injector demonstrates ease of use by adolescents with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis
“Tiredness…That’s the main thing, this is why I work part time.”: A thematic analysis of patient perspectives on care and unmet needs in C3G and primary IC-MPGN
Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.